Kalohexis Unveils Dual MC3R/MC4R Agonist Data at ENDO 2026

The findings, presented by Dr. Jillian L. Seiler of Endevica Bio, detail the performance of 710GO, an oral agonist currently in Phase 1 clinical trials. In studies involving nonhuman primates with diet-induced obesity, the compound achieved an 11.8% reduction in body weight over a 15-week period. Notably, the subjects experienced limited weight rebound after the treatment stopped, a common hurdle in metabolic therapy. Researchers observed that the weight loss was primarily driven by fat reduction, with lean mass largely spared.

Safety data emerged as a critical component of the presentation. Previous attempts to utilize melanocortin agonists for weight loss often faced setbacks due to adverse effects on blood pressure and heart rate. According to Kalohexis, telemetry monitoring in the primate study showed no significant changes in heart rate, blood pressure, or QTc intervals at doses reaching 60 mg/kg. Dr. Daniel Marks, Chief Scientific and Medical Officer at Kalohexis, stated that these results validate the shift toward dual receptor activation as a way to maintain efficacy without compromising cardiovascular stability. The company continues to advance 710GO through its initial human clinical evaluations to determine if these metabolic advantages translate to human patients.